This has created a great surge in demand for treatments for this cancer, but the lack of cases concerning KRAS-mutant lung adenocarcinoma in MENA has been a major setback preventing us from learning more about effective treatment plans. This evidence concerns the gene KRAS and lung adenocarcinoma.